Penpulimab 是一种 IgG1 抗 PD-1 单克隆抗体，具有抗肿瘤活性。
| Cas No. | 2350298-92-7 |
| 别名 | 派安普利单抗 |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Penpulimab is an IgG1 backbone anti-PD-1monoclonal antibody with antitumor activities[1]. Penpulimab demonstrates better stability and a lower level of host-cell protein residue compared with IgG4 backbone anti-PD-1 antibodies[1].
Penpulimab does not mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC) and induces no remarkable IL-6 and IL-8 release by activated macrophages[1].
Penpulimab exhibits slower binding off-rate for human PD-1 than Nivolumab and Pembrolizumab[1].
Penpulimab potentiates T cell activation via PD-1/PD-L1 blockade[1]. Penpulimab (5 mg/kg; i.p.; twice a week, 3weeks) inhibits tumor growth in mice[2]. | Animal Model: | MC38-hPD-L1 tumor-bearing B-hPD-1 humanized mouse model[2] | | Dosage: | 5 mg/kg | | Administration: | IP, twice a week, 3weeks | | Result: | Showed moderate inhibition of tumor growth (tumor volume: 58.4% of control group). Treatment combined with anlotinib (1 mg/kg, every day, p.o) significantly decreased tumor volume to 36.5% of control group. |
|
